# Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

> **NCT05603910** · PHASE1 · RECRUITING · sponsor: **Aaron Wolfson** · enrollment: 18 (estimated)

## Conditions studied

- Recurrent Endometrial Carcinoma
- Unresectable Endometrial Carcinoma

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** Pembrolizumab
- **RADIATION:** Hypofractionated External Beam Radiation Therapy

## Key facts

- **NCT ID:** NCT05603910
- **Lead sponsor:** Aaron Wolfson
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-15
- **Primary completion:** 2027-04-15
- **Final completion:** 2030-04-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05603910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05603910, "Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05603910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*